HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

Table 3 Surgery performed in sixty patients with locally advanced breast cancer subjected to neoadjuvant chemotherapy with docetaxel and epirubicin combination.

	OR N (%)	NR N (%)	P	Test
Clinical Response	46 (76.7)	14 (33.3)	-	-
Surgery
RS	12 (26)	7 (50)
BCS	34 (74)	6 (42.8)
NS	0	1 (7.2)	0.03	x ²
Node
Median (range)	0 (0 – 19)	3 (0 – 25)	0.03	Spearman r

OR = objective response; NR = no response; RS = radical surgery; BCS = breast conserving surgery; NS = not submitted to surgery.

ISSN: 1471-2407